Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	125300
DOI	10.4251/wjgo.125300
Country	China

Category	Gastroenterology & Hepatology
Manuscript Type	Case Report
Article Title	Durable disease control with multimodal treatment including fulzerasib, cetuximab and radiotherapy in locally advanced pancreatic cancer: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Huan Luo, Zheng-Long Zhai, Jian Xu, Xiang Li, Yi-Wen Chen and Xue-Li Bai
Funding Agency and Grant Number	Funding Agency Grant Number Ling Yan Research and Development Program of Department of Zhejiang Province Science and Technology No. 2026C02A1105 and No. 2024C03167
Corresponding Author	Yi-Wen Chen, Department of Hepatobiliary and Pancreatic Surgery, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou 310000, Zhejiang Province, China. cherry0705@zju.edu.cn
Key Words	KRAS G12C mutation; Pancreatic ductal adenocarcinoma; Fulzerasib; cetuximab; Targeted therapy; Precision oncology; Case report
Core Tip	This report presents the first known clinical application of a multimodal regimen combining the KRAS G12C inhibitor fulzerasib, the epidermal growth factor receptor antibody cetuximab, and localized carbon-ion radiotherapy in locally advanced pancreatic cancer harboring a KRAS G12C mutation. The treatment yielded durable disease control, extending progression-free survival beyond 19 months with a manageable safety profile in an 81-year-old patient unfit for conventional chemotherapy. This novel precision approach highlights the potential of combining dual-pathway targeted therapy with heavy-ion radiotherapy for KRAS-mutated locally advanced pancreatic cancer.
Citation	Luo H, Zhai ZL, Xu J, Li X, Chen YW, Bai XL. Durable disease control with multimodal treatment including fulzerasib, cetuximab and radiotherapy in locally advanced pancreatic cancer: A case report. World J Gastrointest Oncol 2026; In press DOI: https://doi.org/10.4251/wjgo.125300
PDF	125300-in-press.pdf

Received	2026-07-06 08:12
Peer-Review Started	2026-07-06 08:12
First Decision by Editorial Office Director
Return for Revision	2026-07-19 03:45
Revised	2026-08-01 10:09
Publication Fee Transferred	2026-08-11 00:04
Second Decision by Editor	2026-09-15 02:45
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-09-15 09:34
Articles in Press	2026-09-15 09:34
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1948-5204 (online)
Open Access	This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com